On January 24, 2019, Mengyang Pharmaceutical welcomed excellent partners from all over the country to the production base, and everyone gathered together to listen to the year-end report, analyze the current situation of the industry, and discuss the future development plan of the enterprise.

In the morning, Vice President Zhou Huiying delivered a welcome speech to the participants and introduced the company's personnel structure. Then, Executive Vice President Huang Yuelai and Vice President Zhang Yueli respectively made a comprehensive and detailed introduction to Mengyang Pharmaceutical production equipment and technology, quality system and product research and development, Chairman Zhang Min deeply interpreted the far-reaching impact of the "4+7 National Centralized Procurement" and "Auxiliary Drug Catalog" policy on the industry, as well as the opportunities brought to the company's products, and introduced the company's continuous improvement of its own process and future strategic planning in the case of a bad external environment over the years. After that, Vice President Huang Yuelai led everyone to visit the production workshop, traditional Chinese medicine pretreatment and extraction building, preparation building and quality inspection center, and introduced the production process characteristics and production capacity of the workshop one by one。

In the afternoon, Ms. Lin Yuefang, sales director, gave a detailed introduction to the market planning and support plan of Mengyang Pharmaceutical in 2019; Product managers Liu Yu and Zhou Peng respectively gave in-depth product training and clinical evidence-based literature explanations to the company's flagship product, Shengbai Oral Liquid (Mixture). In the discussion session that followed, the excellent partners spoke enthusiastically, actively shared clinical sales experience, analyzed future market trends, and discussed the direction of market development.

In the face of change and embracing Mengyang, in the new year, Mengyang people will focus on the precise positioning of the company's products - "treatment drugs for the toxic and side effects of anti-tumor drugs", and are determined to build Mengyang Pharmaceutical into a leading domestic anti-cancer Chinese medicine R&D and production enterprise with "the whole industry chain, the whole product line, and all oral", so as to bring health and hope to more and more cancer patients!